[Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation]
- PMID: 38744543
- DOI: 10.1016/j.bulcan.2024.03.005
[Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation]
Keywords: Aromatase inhibitor; Cancer du sein; ESR1 mutation; Elacestrant; Endocrine therapy; Hormonothérapie; Inhibiteur aromatase; Inhibiteur sélectif du récepteur des œstrogènes; Metastatic breast; Mutation ESR1; Selective estrogen receptor degrader (SERD).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
